Ipilimumab tips

-



  • Ipilimumab is associated with significant toxicities that are immune-related adverse events. 
  • These immune-mediated reactions may involve any organ system; however, the most common immune-adverse reactions are enterocolitis, hepatitis, dermatitis, neuropathy, and endocrinopathy. 
  • Treatment of immune-mediated toxicity requires interruption of ipilimumab and use of corticosteroids depending upon severity of symptoms.
  • The FDA has created a Risk Evaluation and Mitigation Strategy to provide additional information regarding side effects and management of ipilimumab-associated adverse events. 
  • Therefore, it is recommended that patients undergoing treatment with ipilimumab be monitored closely with physical exams, review of symptoms, and blood tests including liver and thyroid function before and during treatment. 
  • Dose modification occurs through withholding a dose, not dose reduction.

Comments

Post a Comment

Popular posts from this blog

Treatment of classical Hodgkin’s lymphoma Summary

-
Early stage favorable Hodgkin’s lymphoma ·          HD 10 trial: NEJM 2010: o    1370 pts, 4 arms: §   4 cycles of ABVD followed by 30 Gy §   4 cycles of ABVD followed by 20 Gy §   2 cycles of ABVD followed by 30 Gy §   2 cycles of ABVD followed by 20 Gy o    No difference in freedom from treatment failure, OS at 5 yrs o    2 cycles of ABVD followed by 20 Gy should be the new standard of care Unfavorable characteristics Bulky disease (>10 cm or 1/3 max. transverse thorax diameter Extranodal site involvement 3 or more lymph node areas involved ESR > 50 mm/h or > 30 mm/hr with B symptoms.                                       ...
Read more

Ovarian Cancer Summary

-
Epidemiology ·          5 th most common cancer among women. ·          Leading cause of gynecologic cancer death. ·          4% of cancers among women in the U.S. ·          Epithelial ovarian cancer accounts for 90% of all cases. ·          Fallopian tube cancer and primary peritoneal cancer are much rare, but share histologic, prognostic and treatment response features with epithelial ovarian cancer. ·          25% of women presents with stage I, 15% with stage II, 42% with stage III and 17% with stage IV. ·          10% of cancers of the ovary are non-epithelial. They are classified as either sex cord stromal cell tumors or germ cell tumors Risk factors and presentation ·   ...
Read more

CLL Summary

-
Epidemiology: CLL is the most prevalent adult leukemia in the western countries. It is more common in men than in women (ratio 1.7 to 1). There is no known risk factors for CLL. Median age at diagnosis between 67 and 72 years. Diagnosis: Sustained increase in mature appearing lymphocytes in the peripheral blood to more than 5,000/mm3. The majority of cases are B-CLL. IHC stains: CD5, low density expression of surface Ig, CD20 & CD22 unlike mantle cell lymphomas which has higher expression of CD20 and surface Ig. The bone marrow usually is infiltrated by at least 30% lymphocytes. Although a bone marrow biopsy is not needed to make the diagnosis, they are strongly recommended if cytopenias in other cell lines are present before starting therapy. Cytogenetic and molecular abnormalities Conventional techniques identify cytogenetic abnormalities in 50% of cases. FISH allows for identification of cytogenetic abnormalities in > 80% of cases...
Read more